Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 377

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes

Open access
Doria, Alessandro, Galecki, Andrzej T., Spino, Cathie, Pop-Busui, Rodica, Cherney, David Z., Lingvay, Ildiko, Parsa, Afshin, Rossing, Peter, Sigal, Ronald J., Afkarian, Maryam, Aronson, Ronnie, Caramori, M. Luiza, Crandall, Jill P., de Boer, Ian H., Elliott, Thomas G., Goldfine, Allison B., Haw, J. Sonya, Hirsch, Irl B., Karger, Amy B., Maahs, David M., McGill, Janet B., Molitch, Mark E., Perkins, Bruce A., Polsky, Sarit, Pragnell, Marlon, Robiner, William N., Rosas, Sylvia E., Senior, Peter, Tuttle, Katherine R., Umpierrez, Guillermo E., Wallia, Amisha, Weinstock, Ruth S., Wu, Chunyi, Mauer, Michael·2020·New England Journal of Medicine
DOI 10.1056/nejmoa1916624
Open this paper in CoChat — free account

Abstract

BACKGROUND: Higher serum urate levels are associated with an increased risk of diabetic kidney disease. Lowering of the serum urate level with allopurinol may slow the decrease in the glomerular filtration rate (GFR) in persons with type 1 diabetes and early-to-moderate diabetic kidney disease. METHODS: of body-surface area, and evidence of diabetic kidney disease to receive allopurinol or placebo. The primary outcome was the baseline-adjusted GFR, as measured with iohexol, after 3 years plus a 2-month washout period. Secondary outcomes included the decrease in the iohexol-based GFR per year and the urinary albumin excretion rate after washout. Safety was also assessed. RESULTS: per year; 95% CI, -1.5 to 0.4). The mean urinary albumin excretion rate after washout was 40% (95% CI, 0 to 80) higher with allopurinol than with placebo. The frequency of serious adverse events was similar in the two groups. CONCLUSIONS: We found no evidence of clinically meaningful benefits of serum urate reduction with allopurinol on kidney outcomes among patients with type 1 diabetes and early-to-moderate diabetic kidney disease. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; PERL ClinicalTrials.gov number, NCT02017171.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1916624

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 377

Metadata

Authors
Doria, A., Galecki, A. T., Spino, C., Pop-Busui, R., Cherney, D. Z., Lingvay, I., Parsa, A., Rossing, P., Sigal, R. J., Afkarian, M., Aronson, R., Caramori, M. L., Crandall, J. P., de Boer, I. H., Elliott, T. G., Goldfine, A. B., Haw, J. S., Hirsch, I. B., Karger, A. B., Maahs, D. M., McGill, J. B., Molitch, M. E., Perkins, B. A., Polsky, S., Pragnell, M., Robiner, W. N., Rosas, S. E., Senior, P., Tuttle, K. R., Umpierrez, G. E., Wallia, A., Weinstock, R. S., Wu, C., & Mauer, M.
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2020-06-25
Volume
382
Issue
26
Pages
2493-2503
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa1916624
OpenAlex
W3037804099
Cited by
377
References
40
FWCI
29.83
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. https://app.cochat.ai/papers/10.1056/nejmoa1916624
The paper
Doria, A., Galecki, A. T., Spino, C., Pop-Busui, R., Cherney, D. Z., Lingvay, I., Parsa, A., Rossing, P., Sigal, R. J., Afkarian, M., Aronson, R., Caramori, M. L., Crandall, J. P., de Boer, I. H., Elliott, T. G., Goldfine, A. B., Haw, J. S., Hirsch, I. B., Karger, A. B., . . . Mauer, M. (2020). Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1916624

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.